The miR-28-5p Targetome Discovery Identified SREBF2 as One of the Mediators of the miR-28-5p Tumor Suppressor Activity in Prostate Cancer Cells.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
03 02 2020
Historique:
received: 12 12 2019
revised: 22 01 2020
accepted: 31 01 2020
entrez: 8 2 2020
pubmed: 8 2 2020
medline: 13 2 2021
Statut: epublish

Résumé

miR-28-5p is downregulated in some tumor tissues in which it has been demonstrated to have tumor suppressor (TS) activity. Here, we demonstrate that miR-28-5p acts as a TS in prostate cancer (PCa) cells affecting cell proliferation/survival, as well as migration and invasion. Using the miRNA pull out assay and next generation sequencing, we collected the complete repertoire of miR-28-5p targets, obtaining a data set (miR-28-5p targetome) of 191 mRNAs. Filtering the targetome with TargetScan 7, PITA and RNA22, we found that 61% of the transcripts had miR-28-5p binding sites. To assign a functional value to the captured transcripts, we grouped the miR-28-5p targets into gene families with annotated function and showed that six transcripts belong to the transcription factor category. Among them we selected SREBF2, a gene with an important role in PCa. We validated miR-28-5p/SREBF2 interaction, demonstrating that SREBF2 inhibition affects almost all the tumor processes altered by miR-28-5p re-expression, suggesting that SREBF2 is an important mediator of miR-28-5p TS activity. Our findings support the identification of the targetome of cancer-related miRNAs as a tool to discover genes and pathways fundamental for tumor development, and potential new targets for anti-tumor therapy.

Identifiants

pubmed: 32028704
pii: cells9020354
doi: 10.3390/cells9020354
pmc: PMC7072282
pii:
doi:

Substances chimiques

MIRN28 microRNA, human 0
MicroRNAs 0
SREBF2 protein, human 0
Sterol Regulatory Element Binding Protein 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Cell Mol Med. 2013 Aug;17(8):1006-15
pubmed: 23802567
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Cell. 2013 Apr 25;153(3):654-65
pubmed: 23622248
Nature. 2008 Oct 23;455(7216):1124-8
pubmed: 18806776
Mol Cancer Ther. 2019 Dec;18(12):2469-2479
pubmed: 31387890
Int J Oncol. 2017 Mar 16;:
pubmed: 28350078
Blood. 2010 Jul 22;116(3):437-45
pubmed: 20445018
Oncol Lett. 2018 Jun;15(6):9777-9785
pubmed: 29928352
Int J Genomics. 2017;2017:5214806
pubmed: 29085832
Mol Cell Biochem. 2015 Oct;408(1-2):283-93
pubmed: 26160280
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W451-4
pubmed: 16845047
Oncogene. 2013 Jan 3;32(1):106-16
pubmed: 22330141
Elife. 2015 Aug 12;4:
pubmed: 26267216
J Cancer. 2017 Aug 22;8(14):2729-2739
pubmed: 28928862
Mol Cancer Ther. 2014 Apr;13(4):855-66
pubmed: 24493696
J Cell Mol Med. 2019 May;23(5):3118-3129
pubmed: 30762286
Blood. 2017 Apr 27;129(17):2408-2419
pubmed: 28188132
Hepatology. 2016 May;63(5):1560-75
pubmed: 26754294
J Cell Biochem. 2019 Jan 16;:
pubmed: 30652355
Nature. 2009 Jul 23;460(7254):479-86
pubmed: 19536157
Prog Lipid Res. 2001 Nov;40(6):439-52
pubmed: 11591434
J Cell Physiol. 2018 Nov;233(11):8919-8929
pubmed: 29856481
Cancer Med. 2017 Jan;6(1):109-119
pubmed: 28035762
Methods. 2007 Oct;43(2):162-5
pubmed: 17889804
BMB Rep. 2017 Nov;50(11):554-559
pubmed: 28946941
Nat Genet. 2018 Feb;50(2):206-218
pubmed: 29335545
Nat Genet. 2007 Oct;39(10):1278-84
pubmed: 17893677
Gastroenterology. 2012 Apr;142(4):886-896.e9
pubmed: 22240480
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9667-72
pubmed: 17535905
Oncotarget. 2016 Nov 8;7(45):73888-73902
pubmed: 27729617
Cell. 2010 Apr 2;141(1):129-41
pubmed: 20371350
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8185-90
pubmed: 24843176
Mol Cell. 2011 Dec 9;44(5):828-40
pubmed: 22152485
Cancer Res. 2004 Mar 15;64(6):2212-21
pubmed: 15026365
RNA. 2008 May;14(5):872-7
pubmed: 18367714
Oncotarget. 2016 Mar 15;7(11):12869-84
pubmed: 26883200
Mol Cell. 2009 Jul 31;35(2):240-6
pubmed: 19647520
Cell. 2006 Sep 22;126(6):1203-17
pubmed: 16990141
Nucleic Acids Res. 2010 Nov;38(20):7211-8
pubmed: 20591824

Auteurs

Sofia Fazio (S)

Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, 56124 Pisa, Italy.
Centre Méditerranéen de Médecin Moléculaire INSERM U1065, Université Côte d'Azur, 06204 Nice, France.

Gabriele Berti (G)

Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, 56124 Pisa, Italy.

Francesco Russo (F)

Institute of Informatics and Telematics (IIT), CNR, 56124 Pisa, Italy.
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Monica Evangelista (M)

Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, 56124 Pisa, Italy.

Romina D'Aurizio (R)

Institute of Informatics and Telematics (IIT), CNR, 56124 Pisa, Italy.

Alberto Mercatanti (A)

Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, 56124 Pisa, Italy.

Marco Pellegrini (M)

Institute of Informatics and Telematics (IIT), CNR, 56124 Pisa, Italy.

Milena Rizzo (M)

Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, 56124 Pisa, Italy.
Tuscan Tumor Institute (ITT), 50139 Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH